References

References

Ahrén B, Dimas AL, Miossec P et al. (2013) Efficacy and safety of lixisenatide once-daily morning or evening injections in type 2 diabetes inadequately controlled on metformin (GetGoal-M). Diabetes Care doi: 10.2337/dc12-2006

European Medicines Agency (2012) Guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus [online; accessed 10 July 2013]

European Medicines Agency (2012) Lyxumia public assessment report [online; accessed 22 July 2013]

European Medicines Agency (2010) Guideline on missing data in confirmatory clinical trials [online; accessed 10 July 2013]

European Medicines Agency (2000) Points to consider on switching between superiority and non-inferiority [online; accessed 10 July 2013]

Fonseca VA, Alvarado-Ruiz R, Raccah D et al. (2012) Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono). Diabetes Care 35: 1225–31 doi: 10.2337/dc11-1935

National Prescribing Centre (2012) Implementing key therapeutic topics: 3, Type 2 diabetes. MeReC Bulletin 22: 5 [online; accessed 28 June 2013]

National Institute for Health and Clinical Excellence (2009) Type 2 diabetes: the management of type 2 diabetes. NICE clinical guideline 87

National Institute for Health and Clinical Excellence (2012) Exenatide prolonged-release suspension for injection in combination with oral antidiabetic therapy for the treatment of type 2 diabetes. NICE technology appraisal guidance 248

National Institute for Health and Clinical Excellence (2010) Liraglutide for the treatment of type 2 diabetes mellitus. NICE technology appraisal guidance 203

Pinget M, Goldenberg R, Niemoeller E et al. (2013) Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone (GetGoal-P). Diabetes, Obesity and Metabolism doi: 10.1111/dom.12121

Riddle MC, Aronson R, Home P et al. (2013a) Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L). Diabetes Care doi: 10.2337/dc12-2454

Riddle MC, Forst T, Aronson R et al. (2013b) Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine; a 24-week, randomized, placebo-controlled study (GETGOAL-DUO-1). Diabetes Care doi: 10.2337/dc12-2462

Rosenstock J, Raccah D, Koranyi L et al. (2013) Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin: a 24-week, randomized, open-label, active-controlled study (GetGoal-X). Diabetes Care doi: 10.2337/dc12-2709

Seino Y, Min KW, Niemoeller E et al. (2012) Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia). Diabetes, Obesity and Metabolism 14: 910–7 doi: 10.1111/j.1463-1326.2012.01618.x

Sanofi (2013) Lyxumia 20 micrograms solution for injection summary of product characteristics [online; accessed 11 July 2013]